SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
53 hedge funds and large institutions have $60.1M invested in Syros Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
53
Holders Change
-14
Holders Change %
-20.9%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
15
Increased
21
Reduced
13
Closed
29
Calls
$1.98M
Puts
$94K
Net Calls
+$1.88M
Net Calls Change
+$1.89M
Top Buyers
| 1 |
AG
Artal Group
Luxembourg
|
+$6.85M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$5.8M |
| 3 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$4.51M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.45M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$3.43M |
Top Sellers
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$481K |
| 2 |
E
Ergoteles
New York
|
-$259K |
| 3 |
Goldman Sachs
New York
|
-$234K |
| 4 |
Millennium Management
New York
|
-$172K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$93K |
